Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 1 diabetes

DEFEND Investigator Group

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 1 diabetes'. Together they form a unique fingerprint.